	US 11,666,563 B2
	Pharmaceutical preparation containing pyridyl aminoacetic acid compound
Hisashi Kawata, Osaka (JP); Noriko Kawabata, Osaka (JP); and Naveed Shams, Emeryville, CA (US)
Assigned to Santen Pharmaceutical Co., Ltd., Osaka (JP)
Appl. No. 16/957,749
Filed by Santen Pharmaceutical Co., Ltd., Osaka (JP)
PCT Filed Dec. 27, 2018, PCT No. PCT/JP2018/048228 § 371(c)(1), (2) Date Jun. 25, 2020, PCT Pub. No. WO2019/131901, PCT Pub. Date Jul. 4, 2019.
Claims priority of provisional application 62/611,017, filed on Dec. 28, 2017.
Prior Publication US 2020/0345713 A1, Nov. 5, 2020
Int. Cl. A61K 31/444 (2006.01); A61K 31/5575 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/444 (2013.01) [A61K 9/0048 (2013.01); A61K 31/5575 (2013.01)]

10 Claims

1. A method of treating primary open angle glaucoma, secondary open angle glaucoma, normal tension glaucoma or ocular hypertension, comprising:

administering to a patient a pharmaceutical preparation containing omidenepag, an ester thereof, or a salt thereof as an active ingredient, wherein the patient is a patient with inadequate efficacies of latanoprost such that, when subjected to treatment with latanoprost, a) a width of decrease between pre-treatment intraocular pressure and post-treatment intraocular pressure is 4.5 mmHg or less, orb) a rate of decrease between pre-treatment intraocular pressure and post-treatment intraocular pressure is 18% or less.